UA138156U - METHOD FOR PREDICTING THE DEVELOPMENT OF OSTEOARTHRITIS - Google Patents

Abstract

The method of predicting the development of osteoarthritis includes clinical examination and radiography. Additionally, in the patient's serum determine the polymorphism of methylenetetrahydrofolate reductase (MTHFR C677T), nitric oxide synthase (eNOS T786C), the content of thrombomodulin, folic acid, oxyproline, C-reactive protein (at 67 thrombomodulin> 5 ng / ml, folic acid <6 ng / ml, oxyproline> 15 μmol / l, PSA> 6 mg / l predict the development of osteoarthritis.

Description

A useful model belongs to medicine, in particular to orthopedics and rheumatology. It is prescribed and can be used in the diagnosis of the development of osteoarthritis in the early stages.

Methods of predicting the development of osteoarthritis are known. These include x-rays, studies of biopsies of the synovial membrane, synovial fluid, and cartilage biopsies (Okorokov

A.N. Diagnosis of diseases of internal organs. - M., 2001. - T. 2. - E. 186-196). The disadvantage of these methods is the inability to predict the dynamics of the process in the early subclinical stages, the inability to prevent its development and possible complications due to the internal characteristics of the body.

The basis of a useful model is the task of developing a method that would allow predicting the development of osteoarthritis in the early stages.

The task is solved by the fact that, in addition to clinical examination and radiography, according to a useful model, the polymorphism of the methylenetetrahydrofolate reductase (MTNEV C677Т), nitric oxide synthase (ЕМО5 1786С), thrombomodulin, folic acid, oxyproline, C-reactive protein (SRP). With homozygous carrier 677-TT, 786-SS, levels of thrombomodulin "5 ng/ml, folic acid "6 ng/ml, oxyproline 215 μmol/l, SRP "b mg/l predict the development of osteoarthritis.

Application of the method. During hospitalization, the patient is examined, x-rays are taken, the polymorphism of MTNEV C677T, eMmo5 T786C genes is determined, the content of thrombomodulin, folic acid, oxyproline, SRP is determined by the immunoenzymatic method. With homozygous carrier 677-TT, 786-

SS, levels of thrombomodulin "5 ng/ml, folic acid "6 ng/ml, oxyproline 215 μmol/l, SRP 26 mg/l predict the development of osteoarthritis.

A specific example of using the method

Patient R., 65 years old, was hospitalized in the clinic due to pain syndrome in the right knee joint. Examined, X-ray taken. No signs of osteoarthritis were found. The polymorphism of MTNEV C677T and emo5 17860 genes was determined in blood serum. The content of thrombomodulin, folic acid, oxyproline, SRP was determined by immunoenzymatic method. A homozygous carrier of 677-TT and 786-SS was established, the levels of thrombomodulin - 12 ng/ml, folic acid - 3.2 ng/ml, oxyproline - 23 μmol/l, SRP - 15 mg/l. The development of osteoarthritis was diagnosed. After 12 months, X-rays revealed signs of osteoarthritis.

Thus, the proposed method is informative and allows diagnosing the development of osteoarthritis at an early stage.

Claims (1)

USEFUL MODEL FORMULA The method of predicting the development of osteoarthritis, which includes a clinical examination, radiography, which is distinguished by the fact that in the patient's blood serum polymorphism of the genes methylenetetrahydrofolate reductase (MTNEV C677Т), nitric oxide synthase (ЕМО5 1786С), the content of thrombomodulin, folic acid, oxyproline, C-reactive protein (SRP) and with homozygous carrier 677-TT, 786-SS and levels of thrombomodulin "5 ng/ml, folic acid "6 ng/ml, oxyproline 215 μmol/l, SRP "6 mg/l predict the development of osteoarthritis.